Adverse events18,473

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 18,473Pages stop at row 10,000

Download this page as JSON

Type	Event	Organ system	Group	Affected	At risk	Events
other	DIARRHOEA	Gastrointestinal disorders	Phase I, Stage 1: GDC-0032 3 Milligrams (mg) Once	1	6	2
other	DIARRHOEA	Gastrointestinal disorders	Phase I, Stage 1: GDC-0032 5 mg QD	2	3	2
other	DIARRHOEA	Gastrointestinal disorders	Phase I, Stage 1: GDC-0032 8 mg QD	1	4	1
other	DIARRHOEA	Gastrointestinal disorders	Phase I, Stage 1: GDC-0032 12 mg QD	7	10	14
other	DIARRHOEA	Gastrointestinal disorders	Phase I, Stage 1: GDC-0032 16 mg QD	9	11	20
other	DIARRHOEA	Gastrointestinal disorders	Phase I, Stage 2: Cohort A - GDC-0032 9 mg QD	10	20	52
other	DIARRHOEA	Gastrointestinal disorders	Phase I, Stage 2: Cohort B - GDC-0032 9 mg QD	16	20	31
other	DIARRHOEA	Gastrointestinal disorders	Phase I, Stage 2: Cohort C - GDC-0032 9 mg QD + Midazolam 5 mg	9	13	13
other	DIARRHOEA	Gastrointestinal disorders	Phase I, Stage 2: Cohort D - GDC-0032 9 mg QD	5	10	10
other	DIARRHOEA	Gastrointestinal disorders	Phase I, Stage 2: Cohort E - GDC-0032 6 mg QD + Letrozole 2.5 mg QD	15	20	38
other	DIARRHOEA	Gastrointestinal disorders	Phase I, Stage 2: Cohort E - GDC-0032 9 mg QD + Letrozole 2.5 mg QD	6	8	11
other	DIARRHOEA	Gastrointestinal disorders	Phase I, Stage 2: Cohort F - GDC-0032 6 mg QD + Fulvestran t 500 mg	14	21	42
other	DIARRHOEA	Gastrointestinal disorders	Phase I, Stage 2: Cohort F - GDC-0032 9 mg QD + Fulvestran t 500 mg	4	6	25
other	DIARRHOEA	Gastrointestinal disorders	Phase I, Stage 2: Cohort G - GDC-0032 9 mg QD	14	21	44
other	DIARRHOEA	Gastrointestinal disorders	Phase I, Stage 2: Cohort H - GDC-0032 6 mg QD	16	35	30
other	DIARRHOEA	Gastrointestinal disorders	Phase I, Stage 2: Cohort J - GDC-0032 4 mg + Fulvestrant 500 mg	11	20	85
other	DIARRHOEA	Gastrointestinal disorders	Phase I, Stage 2: Cohort K - GDC-0032 4 mg + Fulvestrant 500 mg	14	20	71
other	DIARRHOEA	Gastrointestinal disorders	Phase I, Stage 2: Cohort L - GDC-0032 4 mg + Fulvestrant 500 mg	11	19	27
other	DIARRHOEA	Gastrointestinal disorders	Phase I, Stage 2: Cohort M - GDC-0032 2 mg QD + Fulvestrant 500 mg	11	20	27
other	DIARRHOEA	Gastrointestinal disorders	Phase I, Stage 2: Cohort N - GDC-0032 2 mg QD + Letrozole 2.5 mg QD	15	27	29

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01296555/events

API reference For AI assistants

Adverse events18,473

Sources 3

Read this list from software.